Brokerages Set Silence Therapeutics plc (NASDAQ:SLN) Price Target at $33.83

Silence Therapeutics plc (NASDAQ:SLN - Get Free Report) has earned a consensus rating of "Moderate Buy" from the seven brokerages that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation and six have issued a buy recommendation on the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $33.83.

A number of analysts recently commented on the company. Morgan Stanley dropped their price target on Silence Therapeutics from $45.00 to $25.00 and set an "overweight" rating on the stock in a report on Friday, May 9th. BMO Capital Markets lowered their target price on Silence Therapeutics from $67.00 to $25.00 and set an "outperform" rating on the stock in a research note on Tuesday, March 4th. The Goldman Sachs Group cut their price target on shares of Silence Therapeutics from $4.00 to $3.00 and set a "sell" rating on the stock in a report on Friday, May 9th. HC Wainwright restated a "buy" rating and set a $75.00 price objective on shares of Silence Therapeutics in a report on Friday, March 7th. Finally, Chardan Capital lowered their price objective on shares of Silence Therapeutics from $55.00 to $35.00 and set a "buy" rating on the stock in a research report on Friday, May 9th.

Silence Therapeutics Price Performance

Shares of NASDAQ SLN traded down $0.16 during trading on Friday, hitting $5.15. The stock had a trading volume of 57,291 shares, compared to its average volume of 303,128. The firm has a fifty day moving average of $3.95 and a two-hundred day moving average of $4.98. Silence Therapeutics has a 12 month low of $1.97 and a 12 month high of $22.47. The company has a market capitalization of $154.14 million, a PE ratio of -3.28 and a beta of 1.41.

Silence Therapeutics (NASDAQ:SLN - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.42). Silence Therapeutics had a negative net margin of 342.00% and a negative return on equity of 62.81%. The firm had revenue of $0.14 million during the quarter, compared to analysts' expectations of $3.58 million. On average, equities analysts expect that Silence Therapeutics will post -1.77 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Silence Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Bank of America Corp DE boosted its position in Silence Therapeutics by 48,165.6% during the fourth quarter. Bank of America Corp DE now owns 499,066 shares of the company's stock worth $3,434,000 after purchasing an additional 498,032 shares during the period. Barclays PLC boosted its holdings in Silence Therapeutics by 83.8% in the 4th quarter. Barclays PLC now owns 6,126 shares of the company's stock worth $42,000 after buying an additional 2,793 shares during the period. Ameriprise Financial Inc. purchased a new position in Silence Therapeutics in the 4th quarter valued at approximately $113,000. Marshall Wace LLP grew its stake in Silence Therapeutics by 190.3% in the 4th quarter. Marshall Wace LLP now owns 488,889 shares of the company's stock valued at $3,364,000 after buying an additional 320,472 shares in the last quarter. Finally, Nantahala Capital Management LLC raised its holdings in Silence Therapeutics by 424.8% during the 4th quarter. Nantahala Capital Management LLC now owns 1,049,676 shares of the company's stock valued at $7,222,000 after acquiring an additional 849,676 shares during the period. 98.73% of the stock is currently owned by institutional investors.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.